Pharmacokinetics and pharmacodynamics of abarelix, a gonadotropin-releasing hormone antagonist, after subcutaneous continuous infusion in patients with prostate cancer

Clinical Pharmacology and Therapeutics

Volumn 73, Issue 4, 2003, Pages 304-311

  Wong, Shekman L ^a   Lau, David T W ^b   Baughman, Sharon A ^b   Menchaca, Dora ^b   Garnick, Marc B ^b  

^a AMGEN INC   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABARELIX; ANDROSTANOLONE; FOLLITROPIN; GONADORELIN ANTAGONIST; LUTEINIZING HORMONE; PROSTATE SPECIFIC ANTIGEN; TESTOSTERONE;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; HORMONE BLOOD LEVEL; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

AGED; AGED, 80 AND OVER; AREA UNDER CURVE; GONADAL STEROID HORMONES; GONADOTROPIN-RELEASING HORMONE; HALF-LIFE; HUMANS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OLIGOPEPTIDES; PROSTATIC NEOPLASMS;

EID: 0037385257     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(02)17637-5     Document Type: Article

References (11)

1. Garnick MB, Campion M. Abarelix depot, a GnRH antagonist versus LHRH superagonists in prostate cancer: differential effects on follicle-stimulating hormone. Mol Urol 2000;4:275-7.
2. McLeod D, Zinner N, Tomera K, et al. A phase 3, multiple, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. Urology 2001;58:756-61.
3. Tomera K, Gleason D, Gittelman, et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. J Urol 2001;165:1585-9.
4. Fluker MR. Gonadotropin-releasing hormone antagonists. Curr Opin Endocrinol Diabetes 2000;7:350-6.
5. Schally AV. LH-RH analogues: their impact on reproductive medicine. Gynecol Endocrinol 1999;13:401-9.
6. Leroy I, d'Acremont M, Brailly-Tabard S, et al. A single injection of a gonadotropin-releasing hormone (GnRH) antagonist (Cetrorelix) postpones the luteinizing hormone (LH) surge: further evidence for the role of GnRH during the LH surge. Fertil Steril 1994;62:461-7.
7. Hall JE, Whitcomb RW, River JE, et al. Differential regulation of luteinizing hormone, follicle stimulating hormone, and the free alpha-subunit secretion from the gonadotrope by gonadotropin-releasing hormone (GnRH): evidence from the use of two GnRH antagonists. J Clin Endocrinol Metab 1992;75:1220-5.
8. Fluker MR, Monroe SE, Marshall LA, et al. Contrasting effects of a gonadotropin-releasing hormone agonist and antagonist on the secretion of free alpha subunit. Fertil Steril 1994;61:573-5.
9. Wong SL, Lau DT-W, Baughman SA, et al. A novel depot formulation extended the intramuscular delivery of abarelix, a GnRH antagonist in healthy men age 50-75 [abstract]. In: Proceedings of the 2001 Annual American Association of Pharmaceutical Scientists Meeting; 2001 Oct 21-25; Denver, Colo. Denver: The Association; 2001.
10. Duijkers LJM, Klipping C, Willemsen WNP, et al. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotropin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod 1998;13:2392-8.
11. Wong SL, Lau DT-W, Baughman SA, et al. Pharmacokinetic/pharmacodynamic (PK/PD) modeling of the hormonal suppression characteristics of abarelix delivered by a novel depot formulation [abstract]. In: Proceedings of the 2001 Annual American Association of Pharmaceutical Scientists Meeting; 2001 Oct 21-25; Denver, Colo. Denver: The Association; 2001.